Oxford, UK – 21 March 2011: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE: OXB), a leading gene therapy company, today announces that by mutual agreement, its Chairman, Dr Alan Kingsman, will leave the Board of Oxford BioMedica at the Company’s forthcoming Annual General Meeting on 5 May 2011. Nick Rodgers, Non-Executive Director, Senior Independent Director and Deputy Chairman, will then become Chairman.
The Company expresses its deep gratitude to Dr Kingsman for his invaluable contribution to the Company over the last 15 years. Dr Kingsman will continue to be a consultant to Oxford BioMedica.
-Ends-